<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-165909</identifier>
<setSpec>1131-3587</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">United States guidelines on dyslipidemia. strengths and weaknesses</dc:title>
<dc:description xml:lang="en">The American College of Cardiology and the American Heart Association have produced new guidelines on cholesterol levels and the risk of atherosclerotic cardiovascular disease that represent a paradigm shift in the treatment of hypercholesterolemia because they abandon the use of the low-density lipoprotein cholesterol level as the therapeutic target and focus instead on the clinical benefits of statins. This article presents the key features of these guidelines and highlights both their strengths and areas open to improvement (AU)</dc:description>
<dc:creator>Flores Le-Roux, Juana A</dc:creator>
<dc:creator>Chillarón, Juan J</dc:creator>
<dc:creator>Benaiges, David</dc:creator>
<dc:creator>Pedro-Botet, Juan</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El American College of Cardiology y la American Heart Association han formulado nuevas guías sobre cifras de colesterol y riesgo de enfermedad cardiovascular aterosclerótica que aportan un cambio en el paradigma del tratamiento de la hipercolesterolemia, al abandonar el objetivo terapéutico en colesterol unido a lipoproteínas de baja densidad y centrarse en los beneficios clínicos de las estatinas. Se exponen los aspectos fundamentales de esta guía y se destacan los puntos fuertes y los que se podría mejorar (AU)</dc:description>
<dc:source>Rev. esp. cardiol. Supl. (Ed. impresa);15(supl.A): 18a-21a, 2015. tab</dc:source>
<dc:identifier>ibc-165909</dc:identifier>
<dc:title xml:lang="es">Las guías estadounidenses de dislipemia. Fortalezas y debilidades</dc:title>
<dc:subject>^d963^s22073</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d2359^s22080</dc:subject>
<dc:subject>^d30602</dc:subject>
<dc:subject>^d33014^s22073</dc:subject>
<dc:subject>^d50514^s22057</dc:subject>
<dc:subject>^d50504^s22080</dc:subject>
<dc:subject>^d50514^s22016</dc:subject>
<dc:subject>^d14880^s22080</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d8252^s22062</dc:subject>
<dc:type>article</dc:type>
<dc:date>201500</dc:date>
</metadata>
</record>
</ibecs-document>
